Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aileron Therapeutics (ALRN)
:ALRN
Holding ALRN?
Track your performance easily
ALRN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.61 - $7.42
Previous CloseN/A
Volume112.17K
Average Volume (3M)115.50K
Market Cap
$43.12M
Enterprise Value$104.02M
Total Cash (Recent Filing)$20.71M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.78
Next Earnings
Mar 26, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.11
Shares Outstanding21,665,941
10 Day Avg. Volume130,610
30 Day Avg. Volume115,498
Standard Deviation0.38
R-Squared0.10
Alpha-0.00279
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market Cap2.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.58
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Aileron Therapeutics News
PremiumCompany Announcements
Aileron Therapeutics Reports Q3 2024 Financial Results
PremiumPre-Earnings
Is ALRN a Buy, Before Earnings?
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALRN FAQ
What was Aileron Therapeutics’s price range in the past 12 months?
Aileron Therapeutics lowest stock price was $1.61 and its highest was $7.42 in the past 12 months.
What is Aileron Therapeutics’s market cap?
Aileron Therapeutics’s market cap is $43.12M.
When is Aileron Therapeutics’s upcoming earnings report date?
Aileron Therapeutics’s upcoming earnings report date is Mar 26, 2025 which is in 64 days.
How were Aileron Therapeutics’s earnings last quarter?
Aileron Therapeutics released its earnings results on Nov 14, 2024. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.245 by -$0.025.
Is Aileron Therapeutics overvalued?
According to Wall Street analysts Aileron Therapeutics’s price is currently Overvalued.
Does Aileron Therapeutics pay dividends?
Aileron Therapeutics does not currently pay dividends.
What is Aileron Therapeutics’s EPS estimate?
Aileron Therapeutics’s EPS estimate is -0.18.
How many shares outstanding does Aileron Therapeutics have?
Aileron Therapeutics has 21,665,941 shares outstanding.
What happened to Aileron Therapeutics’s price movement after its last earnings report?
Aileron Therapeutics reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.245. Following the earnings report the stock price went down -13.293%.
Which hedge fund is a major shareholder of Aileron Therapeutics?
Currently, no hedge funds are holding shares in ALRN
---
Aileron Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth $897.6 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.0%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.66%
12-Months-Change
Fundamentals
Return on Equity
-54.95%
Trailing 12-Months
Asset Growth
712.80%
Trailing 12-Months
Company Description
Aileron Therapeutics
Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead products candidate, ALRN-6924 which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA.
---
ALRN Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering ALRN
1 Year
1 Year Success Rate
1/3 ratings generated profit
1 Year Average Return
-41.73%
reiterated a buy rating 9 months ago
Copying Aydin Huseynov's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -41.73% per trade.
---